Bioxel signs agreement with two Korean generic drug companies

The names of the companies and the terms of these agreements have not been disclosed for proprietary reasons. Working with its regional marketing representative, Bioxel is actively securing customers for its newest taxane offering in this strategic region.

Thomas Warden, vice-president, sales, marketing and regulatory affairs of Bioxel Pharma, said: “With the use of alternative synthesis processes, like Bioxel’s, and as patent protection expires, generic companies throughout the world are preparing to produce this blockbuster oncology drug. Bioxel expects to be at the forefront of this growth.”